ALNY
ALNYLAM PHARMACEUTICALS, INC.
Latest Form 4:Sale$1.1MbyPYOTT DAVID E I (Director) · filed Jun 3, 2026
ALNYLAM PHARMACEUTICALS, INC. (ALNY) has 48 SEC Form 4 filings (411 transaction rows) in the rolling window, disclosed by 8 distinct insiders. Most recent filing: Jun 3, 2026.
Inside the rolling window, 8 insiders at ALNYLAM PHARMACEUTICALS, INC. reported no open-market purchases and 40 open-market sales totaling $62.2M. The most active filer is CSO & EVP, Head of Research Fitzgerald Kevin Joseph with 10 filings. Insiders have net sold $26.5M over the trailing 6 months. The most recent open-market filing is a sale of 3,830 shares by Director PYOTT DAVID E I, dated Jun 1, 2026, worth $1.1M.
- Industry:Biotechnology
- CEO:Yvonne L. Greenstreet
- Employees:2,500
- HQ:Cambridge, MA, US
- IPO:2004-06-01
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$62.2M
reported sales (SEC code S)
Unique Insiders
8
in the rolling window
Market Cap
$31.7B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
PYOTT DAVID E IFirst filing | Director | Sale | 3,830 | $1.1M | Jun 3 | SEC ↗ |
McLaughlin MelissaFirst filing | Chief Human Resources Officer | Sale | 1,624 | $519K | Apr 7 | SEC ↗ |
McLaughlin MelissaFirst filing | Chief Human Resources Officer | Sale | 2,286 | $755K | Apr 7 | SEC ↗ |
| CSO & EVP, Head of Research | Sale | 633 | $205K | Mar 6 | SEC ↗ | |
| CSO & EVP, Head of Research | Sale | 658 | $213K | Mar 6 | SEC ↗ | |
| EVP Chief R&D | Sale | 2,309 | $746K | Mar 6 | SEC ↗ | |
| EVP Chief R&D | Sale | 2,404 | $779K | Mar 6 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 2,309 | $746K | Mar 6 | SEC ↗ | |
| EVP, Chief Financial Officer | Sale | 2,468 | $797K | Mar 6 | SEC ↗ | |
| Chief Executive Officer | Sale | 2,933 | $948K | Mar 6 | SEC ↗ | |
| EVP Chief R&D | Sale | 1,717 | $563K | Mar 4 | SEC ↗ | |
| EVP Chief R&D | Sale | 1,775 | $568K | Mar 4 | SEC ↗ | |
| CSO & EVP, Head of Research | Sale | 1,598 | $524K | Mar 4 | SEC ↗ | |
| CSO & EVP, Head of Research | Sale | 1,652 | $528K | Mar 4 | SEC ↗ | |
| EVP, Chief Financial Officer | Sale | 2,206 | $723K | Mar 4 | SEC ↗ | |
| Chief Executive Officer | Sale | 6,799 | $2.2M | Mar 4 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 1,598 | $524K | Mar 4 | SEC ↗ | |
| EVP Chief R&D | Sale | 4,627 | $1.5M | Mar 2 | SEC ↗ | |
| CSO & EVP, Head of Research | Sale | 1,959 | $607K | Feb 17 | SEC ↗ | |
| CSO & EVP, Head of Research | Sale | 2,041 | $678K | Feb 17 | SEC ↗ | |
| EVP, Chief Financial Officer | Sale | 2,242 | $695K | Feb 17 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 1,959 | $607K | Feb 17 | SEC ↗ | |
| Chief Executive Officer | Sale | 6,958 | $2.2M | Feb 17 | SEC ↗ | |
| EVP Chief R&D | Sale | 2,242 | $695K | Feb 17 | SEC ↗ | |
Garg PushkalFirst in 3 months | EVP Chief R&D | Sale | 1,510 | $548K | Jan 14 | SEC ↗ |
| CSO & EVP, Head of Research | Sale | 1,510 | $548K | Jan 14 | SEC ↗ | |
| CSO & EVP, Head of Research | Sale | 2,290 | $848K | Jan 14 | SEC ↗ | |
Tanguler TolgaFirst in 3 months | EVP, Chief Commercial Officer | Sale | 1,510 | $548K | Jan 14 | SEC ↗ |
| Chief Executive Officer | Sale | 9,577 | $3.5M | Jan 14 | SEC ↗ | |
Poulton Jeffrey V.First in 3 months | EVP, Chief Financial Officer | Sale | 2,780 | $1.0M | Jan 14 | SEC ↗ |
| CSO & EVP, Head of Research | Sale | 12,128 | $5.5M | Nov 19 | SEC ↗ | |
| Chief Executive Officer | Sale | 15,650 | $7.1M | Nov 14 | SEC ↗ | |
| Chief Executive Officer | Sale | 10,000 | $4.5M | Nov 14 | SEC ↗ | |
Garg PushkalFirst filing | EVP Chief R&D | Sale | 2,937 | $1.3M | Oct 3 | SEC ↗ |
Garg PushkalFirst filing | EVP Chief R&D | Sale | 3,022 | $1.4M | Oct 3 | SEC ↗ |
Tanguler TolgaFirst filing | EVP, Chief Commercial Officer | Sale | 1,405 | $635K | Oct 3 | SEC ↗ |
Poulton Jeffrey V.First filing | EVP, Chief Financial Officer | Sale | 3,821 | $1.7M | Oct 3 | SEC ↗ |
Greenstreet YvonneFirst filing | Chief Executive Officer | Sale | 8,924 | $4.0M | Oct 3 | SEC ↗ |
Fitzgerald Kevin JosephFirst filing | CSO & EVP, Head of Research | Sale | 2,441 | $1.1M | Oct 3 | SEC ↗ |
Reitan Colleen FFirst filing | Director | Sale | 18,000 | $8.4M | Sep 11 | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does ALNY have?
ALNYLAM PHARMACEUTICALS, INC. (ALNY) has 48 SEC Form 4 filings (411 transaction rows) in the rolling 365-day window, disclosed by 8 distinct insiders. Most recent filing: Jun 3, 2026.
When was the most recent SEC Form 4 filing for ALNY?
The most recent Form 4 filing for ALNY on Tracefour is dated Jun 3, 2026.
Who is the most active insider at ALNY?
The most active SEC Form 4 filer at ALNY in the rolling window is CSO & EVP, Head of Research Fitzgerald Kevin Joseph, with 10 filings.
What is the net insider flow at ALNY over the last 6 months?
Over the trailing 180 days, insiders at ALNY have net sold $26.5M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at ALNY in the current window?
Inside the rolling window, insiders at ALNY bought $0 and sold $62.2M based on SEC Form 4 filings.
Can I get alerts for ALNY insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at ALNYLAM PHARMACEUTICALS, INC. (ALNY). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
ALNYLAM PHARMACEUTICALS, INC. is in the Healthcare sector.